Mohamed Tinawi, MD, a nephrologist from Northwest Indiana, provides an update from Kidney Week 2023, discussing several significant studies and trials. Results from the DUPLEX trial, published in The New England Journal of Medicine, demonstrated that sparsentan reduced proteinuria without affecting renal function in patients with primary focal segmental glomerulosclerosis. Results from the ENVISION trial, a phase 2 trial of sibeprenlimab, showed significant proteinuria reduction in patients with IgA nephropathy. Results from the NefigArd phase 3 trial demonstrated that a novel formulation of budesonide slowed the decline in EGFR in patients with IgA nephropathy. A study on ondansetron found a slightly higher risk of sudden cardiac death in dialysis patients. The PROTECT trial demonstrated that sparsentan significantly reduced proteinuria and slowed eGFR decline in patients with IgA nephropathy. A phase 2 clinical trial found that a novel aldosterone synthase inhibitor, BI 690517, reduced proteinuria on top of RA inhibition and empagliflozin. Other study results discussed included the effects of sotagliflozin, glycated albumin, dulaglutide, obinutuzumab, and spironolactone on various kidney-related outcomes.